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Abstract
Background:  Individuals with severe Z α1-antitrypsin (AAT) deficiency have a considerably
increased risk of developing chronic obstructive lung disease (COPD). It has been hypothesized
that compensatory increases in levels of other protease inhibitors mitigate the effects of this AAT
deficiency. We analysed plasma levels of AAT, α1-antichymotrypsin (ACT) and secretory leukocyte
protease inhibitor (SLPI) in healthy (asymptomatic) and COPD subjects with and without AAT
deficiency.
Methods: Studied groups included: 71 asymptomatic AAT-deficient subjects (ZZ, n = 48 and SZ,
n = 23, age 31 ± 0.5) identified during Swedish neonatal screening for AAT deficiency between 1972
and 1974; age-matched controls (MM, n = 57, age 30.7 ± 0.6); older asymptomatic ZZ (n = 10);
healthy MM (n = 20, age 53 ± 9.6); and COPD patients (ZZ, n = 10, age 47.4 ± 11 and MM, n = 10,
age 59.4 ± 6.7). Plasma levels of SLPI, AAT and ACT were analysed using ELISA and
immunoelectrophoresis.
Results: No significant difference was found in plasma ACT and SLPI levels between the healthy
MM and the ZZ or SZ subjects in the studied groups. Independent of the genetic variant, subjects
with COPD (n = 19) had elevated plasma levels of SLPI and ACT relative to controls (n = 153)
(49.5 ± 7.2 vs 40.7 ± 9.1 ng/ml, p < 0.001 and 0.52 ± 0.19 vs 0.40 ± 0.1 mg/ml, p < 0.05, respectively).
Conclusion: Our findings show that plasma levels of ACT and SLPI are not elevated in subjects
with genetic AAT deficiency compared MM controls and do not appear to compensate for the
deficiency of plasma AAT.
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Background
Serine proteases play key roles in coagulation, fibrinolysis,
and in kinin and complement activation. The activities of
these enzymes are controlled at least in part by specific
serine protease inhibitors, most of which are serpins. The
relationship between serine protease and serpin inhibitor
levels has been examined extensively, since an imbalance
between them is linked to local tissue injury and to many
pathologies, including cancer, autoimmune diseases,
chronic obstructive lung disease (COPD), inflammation
and infectious diseases [1-5].
The serine protease inhibitor found in highest concentra-
tion in plasma is α1-antitrypsin (AAT). Severe AAT defi-
ciency in the homozygous Z variant, which differs from
the wild type M variant in the substitution of Glu-342 by
Lys, was first recognized as a hereditary condition predis-
posing to COPD on the basis of low plasma levels (10%
of normal) of AAT [6]. This single amino acid mutation
perturbs the folding and tertiary structure of AAT, leading
to spontaneous polymerization and cellular retention.
Thus, it is a failure in the secretion rather than biosynthe-
sis of AAT that leads to the deficiency [6,7]. AAT is mainly
synthesized by liver cells and the Z variant of AAT is
retained as inclusion bodies in the endoplasmic reticulum
of hepatocytes[8]. These Z-AAT polymers are hypothe-
sized to be cytotoxic and cause liver damage with variable
clinical presentation ranging from neonatal cholestasis to
liver cirrhosis and hepatocellular carcinoma in adults [9-
11].
Individuals with severe AAT deficiency have at least a 20-
fold increased risk of developing lung disease, especially if
they smoke [12]. AAT is the most important inhibitor of
neutrophil elastase and proteinase 3, and it was suggested
that proteases from activated neutrophils, inadequately
regulated by AAT, cause destruction of lung tissue [13].
Other serine protease inhibitors, such as α1-antichymot-
rypsin (ACT), α2-macroglobulin (α2 MG), antithrombin
and antiplasmin, also play important roles in controlling
serine protease activity. While these latter inhibitors are
produced mainly by the liver and reach tissues by passive
diffusion [14], other serine protease inhibitors, such as
Secretory Leukocyte Proteinase Inhibitor (SLPI) and
elafin/SKALP, are produced locally by airway epithelial
cells [15,16]. It was proposed that SLPI, as a major anti-
elastase inhibitor of the bronchi, is important for protect-
ing the respiratory epithelium [17,18]. In contrast to AAT,
SLPI blocks elastin-bound elastase in the alveolar walls,
which might also protect against the development of
COPD [19].
It has been hypothesized that compensatory increases in
other protease inhibitors and/or decreased leukocyte
activity may reduce the severity of AAT deficiency by
favourably affecting the overall protease/protease-inhibi-
tor balance in AAT-deficient individuals [20-22]. To fur-
ther test this hypothesis that compensating increases of
other protease inhibitor concentrations occur in cases
with inherited AAT deficiency, we determined plasma
AAT, ACT and SLPI levels in different age groups of




The first study group included 71 asymptomatic, 31 year
old, AAT-deficient subjects: ZZ, n = 48, 24 females and 24
males, age 31.1 ± 0.52 years and SZ, n = 23, 12 females
and 11 males, age 31 ± 0.58 years, identified in the Swed-
ish neonatal screening study during 1972–1974 [20-22].
Clinical examination, spirometry, and routine blood tests
were performed by a chest physician at the local hospitals.
An age-matched control group MM (n = 57, 33 females
and 24 males, age 31.7 ± 0.6 years) was recruited from the
general population living in the south of Sweden. No sig-
nificant differences in lung function (FEV1  and FEV1/
FVC%) was found among the studied subject groups with
ZZ, SZ and MM variants of AAT.
The second study group consisted of 20 healthy MM AAT
adults (11 males and 9 females, aged 53 ± 9.6 years), 10
asymptomatic ZZ AAT adults (5 males and 5 females, aged
53 ± 9.6 years) and 20 COPD patients, among them 10
patients with ZZ AAT (5 males and 5 females, aged 47.4 ±
11 years) and 10 patients with MM AAT (5 males and 5
females, aged 59.4 ± 6.7 years). COPD was diagnosed
according to the NHLBI/WHO Workshop guidelines [23].
The ZZ and MM COPD patients had a forced expiratory
volume in one second (FEV1) ≤ 80% of that predicted and
a FEV1/Forced vital capacity ratio (FVC) ≤ 70%, while
asymptomatic ZZ individuals had normal lung function.
All COPD patients included in the study were in a stable,
non-exacerbated phase of the disease. The exclusion crite-
ria were liver diseases, vasculitic or other extra-pulmonary
diseases. The control subjects showed no evidence of any
disease and had no respiratory symptoms; none of them
was on medication and all had MM variant and normal
plasma concentration of AAT. The ZZ individuals were
recruited from the Swedish AAT Deficiency Register. The
MM COPD individuals were outpatients at the Depart-
ment of Respiratory Medicine, University Hospital,
Malmo. The healthy volunteers were recruited from the
hospital staff and their relatives. All individuals gave a
signed, informed consent to take part in this study, which
has been approved by the research ethical committee of
Lund University, Sweden.BMC Pulmonary Medicine 2007, 7:1 http://www.biomedcentral.com/1471-2466/7/1
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Blood sample collection
Blood was taken by venipuncture, plasma was directly
separated by centrifugation and stored at -20°C or -80°C
until assayed. AAT-phenotyping was performed by isoe-
lectric focusing at the Department of Clinical Chemistry,
University Hospital.
Assay of SLPI
Secretory leukocyte proteinase inhibitor (SLPI) was ana-
lysed using ELISA kits (R&D Systems Europe Ltd, Abing-
don, UK) according to the manufacturer's instructions.
Absorbance was measured spectrophotometrically at 450
nm using a microplate reader (Labsystems). The mini-
mum detectable level of SLPI was 0, 0625 ng/ml.
Quantitative analysis of ACT and AAT
The plasma concentration of ACT and AAT was deter-
mined by the rocket immunoelectrophoresis method
based on a quantitative estimation of proteins by electro-
phoresis in 1% agarose gel containing monospecific anti-
bodies against ACT or AAT at a concentration of 5.5 μg per
square gel area [23]. The ACT concentration was quanti-
fied by counting the height of the rocket-shaped precipita-
tion zone. For the calibration curve a standard plasma
Seronorm™ with a known concentration of ACT and AAT
was used.
Statistical analysis
The statistical package SPSS for Windows (release 11.5,
SPSS Inc., Chicago) was used for statistical calculations.
Differences in the means were analysed for their statistical
significance with the one-way ANOVA combined with a
multiple-comparisons procedure (Scheffe multiple range
test). The equality of means was analysed for statistical
significance with an independent two sample t-test and
Pearson correlation analysis. Tests showing p < 0.05 were
considered to be significant. Data are expressed as mean ±
SD.
Results
Plasma levels of serine protease inhibitors in 31 year old 
asymptomatic AAT-deficiency and age and gender 
matched MM AAT subjects
As expected, plasma levels of AAT in 31 year old subjects
were ranked: MM>SZ>ZZ and are significantly different
among the groups [F(2/125) = 216, p < 0.001] (Table 1).
However, we found no significant difference in plasma
ACT and SLPI levels between subjects with deficiency of
AAT and subjects with wild type AAT (age and gender
matched controls)
Plasma levels of serine protease inhibitors in older healthy 
(asymptomatic) and COPD subjects with and without 
severe Z AAT deficiency
We found no significant difference in plasma levels of
SLPI and ACT between deficiency and normal AAT sub-
jects in the absence of COPD (Table 2A). For the COPD
cases (Table 2B), the only difference between normal and
AAT deficiency groups is a marginally (within standard
deviation) higher plasma ACT level in the cases with MM
AAT compared to those with ZZ AAT [t(17) = 2.5, p <
0.05)].
Plasma levels of serine protease inhibitors in healthy 
(asymptomatic) and COPD subjects independent of 
genetic variant of AAT and age
It is noteworthy that AAT levels were similar in all asymp-
tomatic ZZ AAT cases independent of age (0.27 ± 0.05 mg/
ml, n = 48, mean age 32 years and 0.2 ± 0.03 mg/ml, n =
10, mean age 53 years), while ZZ COPD patients had 25%
higher plasma AAT levels compared to asymptomatic ZZ
cases, although this was not statistically significant. We
also compared levels of ACT and SLPI in healthy/asymp-
tomatic and COPD individuals independent of the
genetic variant of AAT and age. As shown in Table 3, levels
of both protease inhibitors were found to be elevated in
COPD patients relative to healthy subjects (ACT t(19.4) =
2.8, p < 0.05 and SLPI t(167) = 4.2, p < 0.001). Previous
studies have also demonstrated increased levels of ACT,
SLPI and α2-MG in COPD [24-27].
Discussion
To contain the potential injurious effects of serine pro-
teases, the anti-proteases developed in a parallel network
consisting of "alarm", locally produced such as SLPI and
elafin/ESI/SKALP, and "systemic" inhibitors. The latter,
such as α2-MG, ACT and AAT [28,29], are synthesized
mainly in the liver and can reach the lungs by passive dif-
fusion [30,31]. The point mutations in the gene that result
in plasma deficiency of AAT or ACT are associated with
COPD [32]. However, no polymorphisms have been
reported for SLPI or elafin, and therefore, the question
remains open as to whether a deficit in either SLPI or
elafin contributes to the development of COPD in
patients who otherwise have sufficient levels of AAT and
ACT. On the other hand it has been suggested that
increased plasma levels of other serine protease inhibi-
tors, such as ACT and SLPI, might favourably improve the
protease/anti-protease balance in subjects with severe AAT
deficiency.
To further evaluated this hypothesis, we analysed plasma
levels of AAT, ACT and SLPI and compared in both
healthy and COPD adult patients with and without AAT
deficiency. We analysed these inhibitors in two different
groups of individuals, the first group consisting of 31 yearBMC Pulmonary Medicine 2007, 7:1 http://www.biomedcentral.com/1471-2466/7/1
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old asymptomatic AAT deficiency individuals from the
prospective follow-up study [20], and the second consist-
ing of older asymptomatic and COPD subjects with severe
AAT deficiency from the Malmö AAT Deficiency Register.
Age and gender matched individuals with wild type MM
AAT were used for comparison.
Reports published from the prospective follow-up study
of ZZ and SZ individuals up to age 26 years, focusing on
clinical health, lung and liver function tests and plasma
markers of the protease/protease inhibitor balance, have
shown that ZZ and SZ subjects had significantly higher
plasma concentrations of α2-MG, ACT and antithrombin
III [20] at age 8 and 18 compared with MM control sub-
jects. Recent findings at age 26 for ZZ and SZ subjects with
normal lung function and only marginal deviations in
liver test results showed significantly higher plasma SLPI
levels, but not α2-MG, compared to age matched healthy
MM subjects [20]. In contrast, at age 31, we find in this
study that ZZ and SZ individuals have no significant dif-
ference in plasma SLPI and ACT levels compared to MM
controls. The higher plasma α2-MG, SLPI and ACT levels
reported in AAT deficiency subjects at younger ages were
previously attributed to an unidentified compensatory
mechanism that protects lung tissue against proteolytic
injury under conditions of AAT depletion. Our results
show that this differential is not observed at age 31 and
older, and raise the question of whether the marginal dif-
ferences in protease inhibitor levels observed at younger
ages between AAT deficient subjects and normal are of
clinical importance.
The increased protease inhibitor plasma levels in young
AAT deficiency subjects relative to normal subjects could
be linked to age rather than to a ZZ or SZ phenotype. For
instance, α2-MG levels in cord blood and in young chil-
dren have been found to be very high and to fall fairly rap-
idly from age 15 to 20 years, and to continue to decline
gradually until the age of 30 to 40 [33-35]. Similar meas-
urements in another study found concentrations of α2
MG in normals to be high in youth, reach their minimum
in middle age, and gradually increase with old age [36]. It
has been shown that plasma α2 MG levels in ZZ AAT sub-
jects dropped from 310% at age 8 years to 215% at 18
years and to normal 100% levels at adult age. This pattern
tracked that observed in MM AAT control 8-year olds in
whom the plasma concentrations of α2-MG and α2-
antiplasmin were found to be increased up to 252% and
Table 1: Plasma levels of serine protease inhibitors in 31 year old asymptomatic AAT-deficiency and age and gender matched wild-
type AAT subjects.
AAT-variant N F/M AAT (mg/ml) ACT (mg/ml) SLPI (ng/ml)
Mean ± SD Mean ± SD Mean ± SD
ZZ 48 24/24 0.27 ± 0.05 0.41 ± 0.11 40.2 ± 9.6
SZ 23 12/11 0.64 ± 0.14 0.39 ± 0.08 40.7 ± 8.7
MM 57 33/24 1.44 ± 0.43 0.38 ± 0.08 41.0 ± 7.6
N-number of subjects
SD, standard deviation
Table 2: Plasma levels of serine protease inhibitors in older healthy (asymptomatic) and COPD subjects with and without severe Z 
AAT deficiency.
Healthy (asymptomatic) subjects (A)
AAT-variant N AAT (mg/ml) N ACT (mg/ml) N SLPI (ng/ml)
Mean* ± SD Mean* ± SD Mean* ± SD
ZZ 10 0.20 ± 0.03 10 0.40 ± 0.20 9 44.0 ± 15
MM 20 1.37 ± 0.20 15 0.37 ± 0.15 13 38.2 ± 9.9
COPD subjects (B)
AAT-variant N AAT (mg/ml) N ACT (mg/ml) N SLPI (ng/ml)
Mean* ± SD Mean* ± SD Mean* ± SD
ZZ 10 0.32 ± 0.17 10 0.42 ± 0.12 10 48.5 ± 8.4
MM 10 1.73 ± 0.22 9 0.62 ± 0.21 9 51.1 ± 6.1
N-subject number
* geometric mean value
SD, standard deviationBMC Pulmonary Medicine 2007, 7:1 http://www.biomedcentral.com/1471-2466/7/1
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125% of adult levels (100% corresponding to 2.5 mg/ml
and 70 μg/ml, respectively)[20] and to decline to normal
at adult age. These data indicate an inherent elevation of
α2-MG in the young that is not exclusive to the AAT defi-
cient population.
It is also important to point out that, for example, when
subjects were 26 years old, but not 18 and 31 years old,
SLPI was found to be significantly higher in AAT-deficient
subjects than in wild type controls. These inconsistent
findings during the follow-up studies suggest that plasma
may not be the relevant biological fluid to measure SLPI
levels. Alternatively, because SLPI is produced locally in
the airways and is regulated by various pro-inflammatory
stimuli, its plasma levels when analysed in healthy
(asymptomatic) subjects may not reflect the real situation.
One can not exclude that under inflammatory conditions
the compensatory increase in SLPI and/or other protease
inhibitors may reduce the severity of AAT deficiency by
favourably affecting the overall protease/protease-inhibi-
tor balance in AAT-deficient individuals.
Our data show small increases in ACT and SLPI, as well as
AAT, concentrations in normal MM subjects with COPD
relative to well subjects. These differences exceed those for
the same parameters for ZZ subjects with and without
COPD and suggest that the COPD disease state could con-
found conclusions drawn from comparative studies seek-
ing to attribute phenotypes (elevated protease inhibitor
levels) to genotypes (ZZ, ZS AAT deficiency).
Conclusion
We conclude that there is no clear evidence for compensa-
tory up-regulation of protease inhibitors, such as ACT and
SLPI, in healthy (asymptomatic) subjects with severe AAT
deficiency. Thus, the changes in circulating levels of pro-
tease inhibitors and their likely impact on individual sus-
ceptibility to lung disease remains to be confirmed
through further studies.
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